Molecular characterization of invasive Enterobacteriaceae from pediatric patients in Central and Northwestern Nigeria.
Anti-Bacterial Agents
/ pharmacology
Bacteremia
/ epidemiology
Child, Preschool
Disk Diffusion Antimicrobial Tests
Enterobacteriaceae
/ classification
Enterobacteriaceae Infections
/ epidemiology
Evidence-Based Medicine
Female
Humans
Infant
Introduced Species
Male
Nigeria
/ epidemiology
Population Surveillance
Prevalence
beta-Lactam Resistance
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
02
2020
accepted:
01
09
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
13
11
2020
Statut:
epublish
Résumé
Bacteremia is a leading cause of mortality in developing countries, however, etiologic evaluation is infrequent and empiric antibiotic use not evidence-based. Here, we evaluated the patterns of ESBL resistance in children enrolled into a surveillance study for community acquired bacteremic syndromes across health facilities in Central and Northwestern Nigeria. Blood culture was performed for children aged less than 5 years suspected of having sepsis from Sept 2008-Dec 2016. Blood was incubated using the BACTEC00AE system and Enterobacteriacea identified to the species level using Analytical Profile Index (API20E®). Antibiotic susceptibility profile was determined by the disc diffusion method. Real time PCR was used to characterize genes responsible for ESBL production. Of 21,000 children screened from Sept 2008-Dec 2016, 2,625(12.5%) were culture-positive. A total of 413 Enterobacteriaceae available for analysis were screened for ESBL. ESBL production was detected in 160 Enterobacteriaceae, high resistance rates were observed among ESBL-positive isolates for Ceftriaxone (92.3%), Aztreonam (96.8%), Cefpodoxime (96.3%), Cefotaxime (98.8%) and Trimethoprim/sulfamethoxazole (90%), while 87.5%, 90.7%, and 91.9% of the isolates were susceptible to Imipenem, Amikacin and Meropenem respectively. Frequently detected resistance genes were blaTEM-83.8% (134/160), and, blaCTX-M 83.1% (133/160) followed by blaSHVgenes 66.3% (106/160). Co-existence of blaCTX-M, blaTEM and blaSHV was seen in 94/160 (58.8%), blaCTX-M and blaTEM in 118/160 (73.8%), blaTEM and blaSHV in 97/160 (60.6%) and blaCTX-M and blaSHV in 100/160 (62.5%) of isolates tested. Our results indicate a high prevalence of bacteremia from ESBL Enterobacteriaceae in this population of children. These are resistant to commonly used antibiotics and careful choice of antibiotic treatment options is critical. Further studies to evaluate transmission dynamics of resistance genes could help in the reduction of ESBL resistance in these settings.
Sections du résumé
BACKGROUND
Bacteremia is a leading cause of mortality in developing countries, however, etiologic evaluation is infrequent and empiric antibiotic use not evidence-based. Here, we evaluated the patterns of ESBL resistance in children enrolled into a surveillance study for community acquired bacteremic syndromes across health facilities in Central and Northwestern Nigeria.
METHOD
Blood culture was performed for children aged less than 5 years suspected of having sepsis from Sept 2008-Dec 2016. Blood was incubated using the BACTEC00AE system and Enterobacteriacea identified to the species level using Analytical Profile Index (API20E®). Antibiotic susceptibility profile was determined by the disc diffusion method. Real time PCR was used to characterize genes responsible for ESBL production.
RESULT
Of 21,000 children screened from Sept 2008-Dec 2016, 2,625(12.5%) were culture-positive. A total of 413 Enterobacteriaceae available for analysis were screened for ESBL. ESBL production was detected in 160 Enterobacteriaceae, high resistance rates were observed among ESBL-positive isolates for Ceftriaxone (92.3%), Aztreonam (96.8%), Cefpodoxime (96.3%), Cefotaxime (98.8%) and Trimethoprim/sulfamethoxazole (90%), while 87.5%, 90.7%, and 91.9% of the isolates were susceptible to Imipenem, Amikacin and Meropenem respectively. Frequently detected resistance genes were blaTEM-83.8% (134/160), and, blaCTX-M 83.1% (133/160) followed by blaSHVgenes 66.3% (106/160). Co-existence of blaCTX-M, blaTEM and blaSHV was seen in 94/160 (58.8%), blaCTX-M and blaTEM in 118/160 (73.8%), blaTEM and blaSHV in 97/160 (60.6%) and blaCTX-M and blaSHV in 100/160 (62.5%) of isolates tested.
CONCLUSION
Our results indicate a high prevalence of bacteremia from ESBL Enterobacteriaceae in this population of children. These are resistant to commonly used antibiotics and careful choice of antibiotic treatment options is critical. Further studies to evaluate transmission dynamics of resistance genes could help in the reduction of ESBL resistance in these settings.
Identifiants
pubmed: 33104733
doi: 10.1371/journal.pone.0230037
pii: PONE-D-20-04796
pmc: PMC7588054
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0230037Subventions
Organisme : NIAID NIH HHS
ID : R01 AI097493
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Paediatr Child Health. 2008 Oct;44(10):548-53
pubmed: 18557808
PLoS One. 2014 Jul 17;9(7):e100956
pubmed: 25033234
J Antimicrob Chemother. 2007 Feb;59(2):165-74
pubmed: 17158117
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:159-65
pubmed: 18154540
J Clin Microbiol. 2003 May;41(5):2197-200
pubmed: 12734278
N Engl J Med. 2005 Jan 27;352(4):380-91
pubmed: 15673804
PLoS One. 2017 Sep 12;12(9):e0184592
pubmed: 28898269
Lancet Infect Dis. 2010 Jun;10(6):417-32
pubmed: 20510282
J Pediatr Pharmacol Ther. 2014 Apr;19(2):83-90
pubmed: 25024667
J Clin Microbiol. 2010 Aug;48(8):2840-5
pubmed: 20519460
Saudi J Biol Sci. 2015 Jan;22(1):90-101
pubmed: 25561890
J Clin Diagn Res. 2016 Feb;10(2):DC07-10
pubmed: 27042460
Ann Clin Microbiol Antimicrob. 2010 Jan 12;9:1
pubmed: 20067633
Ann Clin Microbiol Antimicrob. 2012 Jul 23;11:19
pubmed: 22824236
BMC Res Notes. 2009 May 06;2:76
pubmed: 19419535
BMC Infect Dis. 2011 May 19;11:137
pubmed: 21595963
Antimicrob Resist Infect Control. 2018 Feb 20;7:26
pubmed: 29484173
Curr Opin Microbiol. 2005 Oct;8(5):525-33
pubmed: 16129657
Afr J Lab Med. 2012 Jun 04;1(1):16
pubmed: 29062733
BMC Infect Dis. 2015 Jul 07;15:259
pubmed: 26149073
Antimicrob Agents Chemother. 2010 Mar;54(3):1327-30
pubmed: 20047913
BMC Infect Dis. 2016 Jul 11;16:326
pubmed: 27400864
J Antimicrob Chemother. 2018 May 1;73(5):1368-1388
pubmed: 29514211
Int J Antimicrob Agents. 2010 Oct;36(4):355-8
pubmed: 20691573
Lancet Infect Dis. 2008 Mar;8(3):159-66
pubmed: 18291338
J Med Microbiol. 2012 Feb;61(Pt 2):233-238
pubmed: 21940649
J Mol Biol. 2019 Aug 23;431(18):3472-3500
pubmed: 30959050
J Antimicrob Chemother. 2006 Jan;57(1):24-30
pubmed: 16319181
Antimicrob Agents Chemother. 2007 Aug;51(8):2720-5
pubmed: 17548490
Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S325-31
pubmed: 26449948
Bosn J Basic Med Sci. 2011 May;11(2):91-6
pubmed: 21619555
Antimicrob Agents Chemother. 2012 Sep;56(9):4765-70
pubmed: 22733062
Interdiscip Perspect Infect Dis. 2014;2014:819896
pubmed: 24790598
J Clin Diagn Res. 2013 Oct;7(10):2173-7
pubmed: 24298468
Am J Trop Med Hyg. 2016 Feb;94(2):285-8
pubmed: 26643537
BMJ Open. 2019 Mar 1;9(3):e024879
pubmed: 30826764
Trends Microbiol. 2006 Sep;14(9):413-20
pubmed: 16876996
Rev Soc Bras Med Trop. 2015 Mar-Apr;48(2):162-9
pubmed: 25992930